The issued share capital of Medartis comprises 11‘730‘353 registered shares with a nominal value of CHF 0.20 per share. The company has offered 2‘994‘791 newly registered shares and thereby raising around CHF 142.6 Mio. in gross proceeds including all the over-allotment shares. At the opening price of CHF 54.00 per share, the placement volume corresponds (including all the over-allotment shares) to an amount of around CHF 161.7 Mio. The company has granted the Joint Global Coordinators of the offering an over-allotment option of 390‘625 newly registered shares.

Medartis Holding AG, headquartered in Basel, Switzerland, specializes in technically high-precision implants for the surgical fixation of bone fractures and osteotomies. Medartis develops and distributes titanium screws and plates, surgical instruments and system solutions for osteosynthesis in the area of the cranium and extremities. These ensure optimal and quick rehabilitation of the patient after a surgical procedure. Maintaining the highest quality standards, continuous further development and innovation as well as comprehensive services for doctors, OR personnel and patients have top priority. They are crucial for our long-term customer relationships and have formed the basis for sustainable success since the company was founded in 1997. Medartis is represented worldwide with 11 subsidiaries and a broad network of distributors. 


Any questions?

If you have any questions, please do not hesitate to contact Julian Chan, Media Relations.

 
SIX
SIX operates and develops infrastructure services in the areas of securities, payment transactions and financial information with the aim of raising efficiency, quality and innovative capacity across the entire value chain of the Swiss financial center. The company is owned by its users (127 banks). With a workforce of some 4,000 employees and a presence in 23 countries, it generated operating income in excess of CHF 1.9 billion and group net profit of CHF 207.2 million in 2017.
www.six-group.com